{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:34:09Z","timestamp":1793054049570,"version":"4.5.0"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100014824","name":"Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ibroneuroscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.neuroscience.2026.07.022","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:01:04Z","timestamp":1783954864000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The nano-intervention in Huntington\u2019s disease: A theragnostic approach"],"prefix":"10.1016","volume":"612","author":[{"given":"Ayush","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Prakash","family":"Dewangan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhant","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shagufta","family":"Parveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-769X","authenticated-orcid":false,"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuroscience.2026.07.022_b0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF02742437","article-title":"The early cellular pathology of Huntington\u2019s disease","volume":"20","author":"Li","year":"1999","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.neuroscience.2011.08.052","article-title":"Pathophysiology of Huntington\u2019s disease: time-dependent alterations in synaptic and receptor function","volume":"198","author":"Raymond","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0015","first-page":"506","article-title":"Huntington disease: genetics and epidemiology","volume":"36","author":"Conneally","year":"1984","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0020","doi-asserted-by":"crossref","unstructured":"Kay C, Hayden MR, Leavitt BR. Epidemiology of Huntington disease, 2017, p. 31\u201346. doi: 10.1016\/B978-0-12-801893-4.00003-1.","DOI":"10.1016\/B978-0-12-801893-4.00003-1"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ejhg.2010.229","article-title":"HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia","volume":"19","author":"Warby","year":"2011","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0030","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of Huntington\u2019s disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0035","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)60111-1","article-title":"Huntington\u2019s disease","volume":"369","author":"Walker","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0040","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jconrel.2011.08.017","article-title":"Transport of drugs across the blood\u2013brain barrier by nanoparticles","volume":"161","author":"Wohlfart","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0045","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1039\/C5TB00617A","article-title":"Polymeric multifunctional nanomaterials for theranostics","volume":"3","author":"Peng","year":"2015","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0050","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1166\/jbn.2017.2407","article-title":"Synthesis and in vitro characterization of carboxymethyl chitosan-CBA-doxorubicin conjugate nanoparticles as ph-sensitive drug delivery systems","volume":"13","author":"Hu","year":"2017","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0055","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2217\/nnm.16.9","article-title":"Recent advances in liposome surface modification for oral drug delivery","volume":"11","author":"Nguyen","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0060","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1471-2202-9-S3-S4","article-title":"Nanotechnology approaches to crossing the blood-brain barrier and drug delivery to the CNS","volume":"9","author":"Silva","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1166\/jnn.2014.8757","article-title":"Functional nanoparticles in targeting glioma diagnosis and therapies","volume":"14","author":"Li","year":"2014","journal-title":"J. Nanosci. Nanotechnol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0070","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.nano.2011.02.008","article-title":"Could nanoparticle systems have a role in the treatment of cerebral gliomas?","volume":"7","author":"Caruso","year":"2011","journal-title":"Nanomedicine"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0169-409X(00)00122-8","article-title":"Nanoparticulate systems for brain delivery of drugs","volume":"47","author":"Kreuter","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0080","doi-asserted-by":"crossref","unstructured":"PARDRIDGE WM. Receptor-Mediated Peptide Transport through the Blood-Brain Barrier*. Endocr Rev 1986;7:314\u201330. doi: 10.1210\/edrv-7-3-314.","DOI":"10.1210\/edrv-7-3-314"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0085","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejpb.2009.09.003","article-title":"Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters","volume":"74","author":"Gelperina","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jconrel.2006.10.015","article-title":"Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: Revisiting the role of surfactants","volume":"117","author":"Petri","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0095","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jconrel.2008.10.016","article-title":"Lactoferrin-conjugated PEG\u2013PLA nanoparticles with improved brain delivery: In vitro and in vivo evaluations","volume":"134","author":"Hu","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0100","doi-asserted-by":"crossref","first-page":"16889","DOI":"10.1073\/pnas.1420103111","article-title":"Potential function for the Huntingtin protein as a scaffold for selective autophagy","volume":"111","author":"Ochaba","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0105","doi-asserted-by":"crossref","unstructured":"Reiner A, Dragatsis I, Dietrich P. Genetics and Neuropathology of Huntington\u2019s Disease, 2011, p. 325\u201372. doi: 10.1016\/B978-0-12-381328-2.00014-6.","DOI":"10.1016\/B978-0-12-381328-2.00014-6"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10048-004-0198-8","article-title":"NR2A and NR2B receptor gene variations modify age at onset in Huntington disease","volume":"6","author":"Arning","year":"2005","journal-title":"Neurogenetics"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JHD-160205","article-title":"Oxidative stress and Huntington\u2019s disease: the good, the bad, and the ugly","volume":"5","author":"Kumar","year":"2016","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10863-010-9288-5","article-title":"Mitochondrial functional alterations in relation to pathophysiology of Huntington\u2019s disease","volume":"42","author":"Pandey","year":"2010","journal-title":"J. Bioenerg. Biomembr."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0125","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment of Huntington\u2019s disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0130","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/nrn1806","article-title":"Normal huntingtin function: an alternative approach to Huntington\u2019s disease","volume":"6","author":"Cattaneo","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0135","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0166-2236(00)01609-X","article-title":"Transcriptional dysregulation in Huntington\u2019s disease","volume":"23","author":"Cha","year":"2000","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0140","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/39885","article-title":"Anterograde transport of brain-derived neurotrophic factor and its role in the brain","volume":"389","author":"Altar","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0145","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1523\/JNEUROSCI.15-07-05297.1995","article-title":"NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum","volume":"15","author":"Landwehrmeyer","year":"1995","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0150","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1523\/JNEUROSCI.5599-08.2009","article-title":"In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease","volume":"29","author":"Heng","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/1073858420972662","article-title":"Synaptic dysfunction in Huntington\u2019s disease: lessons from genetic animal models","volume":"28","author":"Cepeda","year":"2022","journal-title":"Neuroscientist"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1471-4159.1992.tb09283.x","article-title":"Increased cerebrospinal fluid dopamine and 3,4\u2010dihydroxyphenylacetic acid levels in Huntington\u2019s disease: evidence for an overactive dopaminergic brain transmission","volume":"58","author":"Garrett","year":"1992","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0165","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.molbrainres.2003.08.009","article-title":"Analysis of cellular, transgenic and human models of Huntington\u2019s disease reveals tyrosine hydroxylase alterations and substantia nigra neuropathology","volume":"119","author":"Yohrling","year":"2003","journal-title":"Mol. Brain Res."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0170","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1021\/acsnano.7b07625","article-title":"Tau-targeted multifunctional nanocomposite for combinational therapy of Alzheimer\u2019s disease","volume":"12","author":"Chen","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0175","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2013.00114","article-title":"Dopamine imbalance in Huntington\u2019s disease: a mechanism for the lack of behavioral flexibility","volume":"7","author":"Chen","year":"2013","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0180","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s13023-023-02930-z","article-title":"The improvement of motor symptoms in Huntington\u2019s disease during cariprazine treatment","volume":"18","author":"Csehi","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105642","article-title":"Recent developments in the management of Huntington\u2019s disease","volume":"120","author":"Devadiga","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0190","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/ajmg.a.38494","article-title":"Therapy development in Huntington disease: from current strategies to emerging opportunities","volume":"176","author":"Dickey","year":"2018","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0195","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders","volume":"11","author":"Jankovic","year":"2011","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/mdc3.12483","article-title":"Tetrabenazine versus deutetrabenazine for huntington\u2019s disease: twins or distant cousins?","volume":"4","author":"Rodrigues","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105642","article-title":"Recent developments in the management of Huntington\u2019s disease","volume":"120","author":"Devadiga","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0210","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/mds.26014","article-title":"Current therapeutic options for Huntington\u2019s disease: good clinical practice versus evidence\u2010based approaches?","volume":"29","author":"Killoran","year":"2014","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0215","doi-asserted-by":"crossref","unstructured":"van Duijn E. Medical treatment of behavioral manifestations of Huntington disease, 2017, p. 129\u201339. doi: 10.1016\/B978-0-12-801893-4.00011-0.","DOI":"10.1016\/B978-0-12-801893-4.00011-0"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0220","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1038\/s41380-022-01511-z","article-title":"The blood-brain barrier in aging and neurodegeneration","volume":"27","author":"Knox","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0225","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2022.147937","article-title":"Factors influencing the blood-brain barrier permeability","volume":"1788","author":"Zhao","year":"2022","journal-title":"Brain Res."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0235","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190062","article-title":"The blood\u2013brain barrier in health and disease: important unanswered questions","volume":"217","author":"Profaci","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0240","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood\u2013brain barrier: structure, regulation and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0245","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41573-021-00139-y","article-title":"Strategies for delivering therapeutics across the blood\u2013brain barrier","volume":"20","author":"Terstappen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0250","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jconrel.2020.11.021","article-title":"Neurodegenerative diseases and effective drug delivery: a review of challenges and novel therapeutics","volume":"330","author":"Akhtar","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0255","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0260","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.1021\/acs.jmedchem.2c01824","article-title":"Explaining blood\u2013brain barrier permeability of small molecules by integrated analysis of different transport mechanisms","volume":"66","author":"Cornelissen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0265","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s11064-021-03488-7","article-title":"Lipid-based nanocarriers via nose-to-brain pathway for central nervous system disorders","volume":"47","author":"Nguyen","year":"2022","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0270","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17425247.2018.1429401","article-title":"Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery","volume":"15","author":"Battaglia","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0275","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jconrel.2020.02.015","article-title":"Nanocarrier-mediated brain delivery of bioactives for treatment\/prevention of neurodegenerative diseases","volume":"321","author":"Babazadeh","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0280","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s13534-021-00198-5","article-title":"Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases","volume":"11","author":"Seo","year":"2021","journal-title":"Biomed. Eng. Lett."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0285","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1021\/acs.molpharmaceut.5c00386","article-title":"Intranasal therapeutics for neurodegenerative disorders: overcoming the blood\u2013brain barrier with smart formulations and devices","volume":"22","author":"Kumar","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0290","article-title":"Intranasal drug delivery: unlocking the nose-to-brain route for central nervous system therapies","volume":"11","author":"Alwali","year":"2026","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0295","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2147\/IJN.S439181","article-title":"Recent advances in intranasal administration for brain-targeting delivery: a comprehensive review of lipid-based nanoparticles and stimuli-responsive gel formulations","volume":"19","author":"Koo","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0300","first-page":"480","article-title":"Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: Focus on recent advances","volume":"14","author":"Niu","year":"2019","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/B978-0-323-99616-7.00005-0","article-title":"Advanced drug delivery systems to treat Huntington\u2019s disease: challenges and opportunities","author":"Vishwas","year":"2022","journal-title":"Drug Delivery Systems for Metabolic Disorders, Elsevier"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117394","article-title":"Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer\u2019s, Parkinson\u2019s and Prion\u2019s","volume":"245","author":"Nirale","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0315","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3390\/pharmaceutics12121230","article-title":"Intranasal nanoemulsions for direct nose-to-brain delivery of actives for CNS disorders","volume":"12","author":"Bahadur","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2020.104917","article-title":"Intranasal delivery of tetrabenazine nanoemulsion via olfactory region for better treatment of hyperkinetic movement associated with Huntington\u2019s disease: Pharmacokinetic and brain delivery study","volume":"230","author":"Arora","year":"2020","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0325","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.2147\/IJN.S183117","article-title":"Liposome delivery systems for the treatment of Alzheimer\u2019s disease","volume":"13","author":"Ross","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0330","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.4103\/1673-5374.327328","article-title":"Liposome based drug delivery as a potential treatment option for Alzheimer\u2019s disease","volume":"17","author":"Hernandez","year":"2022","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101806","article-title":"Current advancements related to phytobioactive compounds based liposomal delivery for neurodegenerative diseases","volume":"83","author":"Khot","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0340","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.addr.2012.09.041","article-title":"Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances","volume":"65","author":"Xu","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0345","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.drudis.2018.11.001","article-title":"Strategies for brain-targeting liposomal delivery of small hydrophobic molecules in the treatment of neurodegenerative diseases","volume":"24","author":"Wang","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0350","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2174\/2468187313666230228102211","article-title":"Liposomal drug delivery system as an emerging technique for treatment of \u201cneurodegenerative diseases.","volume":"13","author":"Agiwale","year":"2023","journal-title":"Current Nanomedicine"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0355","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s12035-020-02232-6","article-title":"Cholesterol metabolism in neurodegenerative diseases: molecular mechanisms and therapeutic targets","volume":"58","author":"Dai","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0360","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.mcn.2009.07.013","article-title":"Cholesterol involvement in the pathogenesis of neurodegenerative diseases","volume":"43","author":"Liu","year":"2010","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0365","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2017.00382","article-title":"Intracellular cholesterol trafficking and impact in neurodegeneration","volume":"10","author":"Arenas","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0370","first-page":"33","article-title":"Vonsattel J-PG, faull RL","author":"Waldvogel","year":"2014","journal-title":"The Neuropathology of Huntington\u2019s Disease"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0375","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2217\/nnm-2019-0443","article-title":"Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases","volume":"15","author":"Cano","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0380","first-page":"1","article-title":"The antiaggregative and antiamyloidogenic properties of nanoparticles: a promising tool for the treatment and diagnostics of neurodegenerative diseases","volume":"2020","author":"Pichla","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0385","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood\u2013brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0390","doi-asserted-by":"crossref","first-page":"24126","DOI":"10.1021\/acsami.7b06510","article-title":"Poly(trehalose) nanoparticles prevent amyloid aggregation and suppress polyglutamine aggregation in a Huntington\u2019s disease model mouse","volume":"9","author":"Debnath","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0395","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.addr.2019.02.007","article-title":"Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders","volume":"148","author":"Vissers","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0400","first-page":"183","article-title":"Metal nanoparticles for neurodegenerative diseases. Nanomedical drug delivery for neurodegenerative diseases","author":"Haque","year":"2022","journal-title":"Elsevier"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113305","article-title":"Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: at a glance","volume":"153","author":"Rahman","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0410","doi-asserted-by":"crossref","first-page":"5106","DOI":"10.1021\/acsanm.2c03936","article-title":"Iron oxide nanoparticle-mediated siRNA delivery system for Huntington\u2019s disease treatment","volume":"6","author":"Rohiwal","year":"2023","journal-title":"ACS Appl. Nano Mater."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0415","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1039\/C8CS00986D","article-title":"Metal-based imaging agents: progress towards interrogating neurodegenerative disease","volume":"49","author":"Sedgwick","year":"2020","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0420","doi-asserted-by":"crossref","first-page":"34725","DOI":"10.1021\/acsami.9b12319","article-title":"Selenium nanoparticles as an efficient nanomedicine for the therapy of Huntington\u2019s disease","volume":"11","author":"Cong","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0425","doi-asserted-by":"crossref","DOI":"10.34172\/apb.2022.077","article-title":"Inorganic nanoparticles: toxic effects, mechanisms of cytotoxicity and phytochemical interactions","author":"Bhatti","year":"2021","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0430","article-title":"Pharmacokinetics and toxicity of inorganic nanoparticles and the physicochemical properties\/factors affecting them","volume":"99","author":"Saker","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0435","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.actbio.2024.09.027","article-title":"Navigating neurotoxicity and safety assessment of nanocarriers for brain delivery: strategies and insights","volume":"189","author":"Teixeira","year":"2024","journal-title":"Acta Biomater."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0440","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3390\/nano12142337","article-title":"Inorganic nanomaterials versus polymer-based nanoparticles for overcoming neurodegeneration","volume":"12","author":"Martano","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.jics.2021.100011","article-title":"Current status, challenges and future directions in the treatment of neurodegenerative diseases by polymeric materials","volume":"98","author":"Ghosh","year":"2021","journal-title":"J. Indian Chem. Soc."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0450","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/jfb10010004","article-title":"Biocompatible polymer nanoparticles for drug delivery applications in cancer and neurodegenerative disorder therapies","volume":"10","author":"Calzoni","year":"2019","journal-title":"J Funct Biomater"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101658","article-title":"Brain drug delivery and neurodegenerative diseases: polymeric PLGA-based nanoparticles as a forefront platform","volume":"79","author":"Pinto","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0460","article-title":"Enriched chitosan nanoparticles loaded with siRNA are effective in lowering Huntington\u2019s disease gene expression following intranasal administration","volume":"24","author":"Sava","year":"2020","journal-title":"Nanomedicine"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0465","doi-asserted-by":"crossref","unstructured":"Applications of Nanostructured Lipid Carriers: Recent Advancements and Patent Review. Biointerface Res Appl Chem 2021;12:638\u201352. doi: 10.33263\/BRIAC121.638652.","DOI":"10.33263\/BRIAC121.638652"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0470","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1218625","article-title":"Theoretical design for covering Engeletin with functionalized nanostructure-lipid carriers as neuroprotective agents against Huntington\u2019s disease via the nasal-brain route","volume":"14","author":"Smriti","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0475","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0480","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejpb.2020.01.005","article-title":"Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases","volume":"149","author":"Teixeira","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0485","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","article-title":"Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases","volume":"264","author":"Tapeinos","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0490","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/pharmaceutics12100928","article-title":"Nanostructured lipid carriers made of \u03a9-3 polyunsaturated fatty acids: in vitro evaluation of emerging nanocarriers to treat neurodegenerative diseases","volume":"12","author":"Hernando","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0495","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/17425247.2016.1178237","article-title":"Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases","volume":"13","author":"Cacciatore","year":"2016","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0500","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/pharmaceutics13081183","article-title":"Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB","volume":"13","author":"Satapathy","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0505","doi-asserted-by":"crossref","first-page":"6553","DOI":"10.2174\/1381612824666171128105305","article-title":"Intranasal lipid nanoparticles for the treatment of neurodegenerative diseases","volume":"23","author":"Cunha","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0510","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1021\/acschemneuro.1c00540","article-title":"Engineered solid lipid nanoparticles and nanostructured lipid carriers as new generations of blood\u2013brain barrier transmitters","volume":"12","author":"Amiri","year":"2021","journal-title":"ACS Chem. Nerosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0515","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3109\/10717544.2014.880860","article-title":"Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington\u2019s disease","volume":"22","author":"Bhatt","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0520","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.3390\/ijms22084085","article-title":"Emerging roles of exosomes in Huntington\u2019s disease","volume":"22","author":"Ananbeh","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0525","doi-asserted-by":"crossref","first-page":"45","DOI":"10.14802\/jmd.16054","article-title":"Exosome-based delivery of miR-124 in a Huntington\u2019s disease model","volume":"10","author":"Lee","year":"2017","journal-title":"J Mov Disord"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0530","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1085057","article-title":"The emerging role of exosomes in innate immunity, diagnosis and therapy","volume":"13","author":"Gangadaran","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0535","first-page":"124","article-title":"Exosome regulation of immune response mechanism: pros and cons in immunotherapy","volume":"32","author":"Essola","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0540","article-title":"Neurodegenerative diseases and brain delivery of therapeutics: bridging the gap using dendrimers","volume":"87","author":"Kaur","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0545","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.progpolymsci.2016.09.006","article-title":"Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches","volume":"64","author":"Mignani","year":"2017","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0550","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ijpharm.2018.04.032","article-title":"PAMAM dendrimers as a carbamazepine delivery system for neurodegenerative diseases: a biophysical and nanotoxicological characterization","volume":"544","author":"Igart\u00faa","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0555","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3390\/molecules23092238","article-title":"Use of polyamidoamine dendrimers in brain diseases","volume":"23","author":"Florendo","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0560","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4161\/pri.24431","article-title":"Nanomedicine for prion disease treatment","volume":"7","author":"McCarthy","year":"2013","journal-title":"Prion"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0565","doi-asserted-by":"crossref","first-page":"37383","DOI":"10.1021\/acsami.5c07366","article-title":"The nanocarrier landscape\u2500evaluating key drug delivery vehicles and their capabilities: a translational perspective","volume":"17","author":"Khalid-Salako","year":"2025","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0570","article-title":"Regulatory pathways and guidelines for nanotechnology-enabled health products: a comparative review of EU and US frameworks","volume":"12","author":"Rodr\u00edguez-G\u00f3mez","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0575","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202400280","article-title":"Transformative impact of nanocarrier\u2010mediated drug delivery: overcoming biological barriers and expanding therapeutic horizons","volume":"4","author":"Kim","year":"2024","journal-title":"Small Sci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2024.216206","article-title":"Advances in nanotherapeutic strategies for Huntington\u2019s disease: design, delivery, and neuroprotective mechanisms","volume":"522","author":"Khan","year":"2025","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0585","doi-asserted-by":"crossref","first-page":"73809","DOI":"10.1007\/s11356-022-22830-2","article-title":"Focusing the pivotal role of nanotechnology in Huntington\u2019s disease: an insight into the recent advancements","volume":"29","author":"Singh","year":"2022","journal-title":"Environ. Sci. Pollut. Res."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0590","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.3390\/pharmaceutics13122055","article-title":"Nanotechnology-based drug delivery strategies to repair the mitochondrial function in neuroinflammatory and neurodegenerative diseases","volume":"13","author":"Gonz\u00e1lez","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0595","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s12640-021-00468-1","article-title":"Nanotechnology in improving the treatment of Huntington\u2019s disease: a systematic review","volume":"40","author":"Valad\u00e3o","year":"2022","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0600","article-title":"Advances in nanotechnology versus stem cell therapy for the theranostics of Huntington\u2019s disease","volume":"87","author":"Mustafa","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0605","first-page":"1","article-title":"Surface-engineered precision nano-systems for targeted treatment of Huntington\u2019s disease: a review of recent advancements","volume":"21","author":"Zhang","year":"2026","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0610","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2024.01.011","article-title":"Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease","volume":"367","author":"Caron","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0615","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41582-019-0211-3","article-title":"Antisense oligonucleotide reduces mutant protein in patients with HD","volume":"15","author":"Lempri\u00e8re","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0620","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40259-022-00519-9","article-title":"Antisense oligonucleotide therapy: from design to the Huntington disease clinic","volume":"36","author":"Rook","year":"2022","journal-title":"BioDrugs"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0625","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.1038\/s41467-022-33061-x","article-title":"Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington\u2019s disease models","volume":"13","author":"Conroy","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0630","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40035-017-0101-9","article-title":"RNAi mechanisms in Huntington\u2019s disease therapy: siRNA versus shRNA","volume":"6","author":"Aguiar","year":"2017","journal-title":"Transl Neurodegener"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0635","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejpb.2021.11.003","article-title":"Modified cyclodextrin-based nanoparticles mediated delivery of siRNA for huntingtin gene silencing across an in vitro BBB model","volume":"169","author":"Mendon\u00e7a","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0640","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(11)70070-9","article-title":"Development of biomarkers for Huntington\u2019s disease","volume":"10","author":"Weir","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JHD-160196","article-title":"Cerebrospinal fluid biomarkers for Huntington\u2019s disease","volume":"5","author":"Byrne","year":"2016","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0650","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mcn.2019.02.004","article-title":"Fluid and imaging biomarkers for Huntington\u2019s disease","volume":"97","author":"Zeun","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0655","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.brainresrev.2008.04.001","article-title":"Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington\u2019s disease","volume":"58","author":"Bohanna","year":"2008","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0660","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.mjafi.2012.08.002","article-title":"Imaging of Huntington\u2019s disease","volume":"70","author":"Negi","year":"2014","journal-title":"Med. J. Armed Forces India"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0665","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4329\/wjr.v6.i6.301","article-title":"Neuroimaging in Huntington\u2019s disease","volume":"6","author":"Niccolini","year":"2014","journal-title":"World J. Radiol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0670","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11910-018-0890-y","article-title":"Novel imaging biomarkers for Huntington\u2019s disease and other hereditary choreas","volume":"18","author":"Fazio","year":"2018","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2023.105488","article-title":"Neuroimaging biomarkers in Huntington\u2019s disease: preparing for a new era of therapeutic development","volume":"114","author":"van Eimeren","year":"2023","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0680","doi-asserted-by":"crossref","DOI":"10.1177\/15491684261417549","article-title":"Huntington\u2019s disease: an overview of biomarkers in prognostic, diagnostic, and therapeutic management","author":"Singh","year":"2026","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0685","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/978-1-4939-7825-0_17","article-title":"Biofluid biomarkers in Huntington\u2019s disease","author":"Rodrigues","year":"2018","journal-title":"Huntington's Disease"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0690","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1038\/s41598-023-32630-4","article-title":"Quantifying mutant huntingtin protein in human cerebrospinal fluid to support the development of huntingtin-lowering therapies","volume":"13","author":"Vauleon","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102710","article-title":"Molecular and imaging biomarker responses to brain mutant HTT lowering in a mouse model of Huntington disease","volume":"36","author":"Caron","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0700","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s00415-023-11572-x","article-title":"The updated development of blood-based biomarkers for Huntington\u2019s disease","volume":"270","author":"Zhang","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0705","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JHD-170245","article-title":"Fifteen years of clinical trials in Huntington\u2019s disease: a very low clinical drug development success rate","volume":"6","author":"Travessa","year":"2017","journal-title":"J Huntingtons Dis"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0710","first-page":"69","article-title":"Clinical trials for huntington disease","author":"Rocha","year":"2020","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0715","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12017-013-8261-y","article-title":"Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of Huntington\u2019s disease","volume":"16","author":"Sandhir","year":"2014","journal-title":"NeuroMol. Med."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0720","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/nnm-2020-0239","article-title":"Epigallocatechin-3-gallate PEGylated Poly(Lactic-Co-Glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice","volume":"16","author":"Cano","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.neuroscience.2026.07.022_b0725","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1021\/jacs.8b11441","article-title":"TiO 2 nanoparticles catalyze oxidation of huntingtin exon 1-derived peptides impeding aggregation: a quantitative NMR study of binding and kinetics","volume":"141","author":"Ceccon","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0730","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cbi.2016.05.020","article-title":"A novel therapeutic application of solid lipid nanoparticles encapsulated thymoquinone (TQ-SLNs) on 3-nitroproponic acid induced Huntington\u2019s disease-like symptoms in wistar rats","volume":"256","author":"Ramachandran","year":"2016","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.neuroscience.2026.07.022_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119248","article-title":"MnFe2O4 nanoparticles accelerate the clearance of mutant huntingtin selectively through ubiquitin-proteasome system","volume":"216","author":"Zhang","year":"2019","journal-title":"Biomaterials"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226004665?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452226004665?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:42:52Z","timestamp":1793050972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452226004665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":147,"alternative-id":["S0306452226004665"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.07.022","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The nano-intervention in Huntington\u2019s disease: A theragnostic approach","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2026.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}